产时缩宫素输注最大剂量率与产科及围产结局的关系
本研究为双盲、单中心随机对照试验的二次分析,纳入1003例36周及以上自然临产的单胎初产妇,其中955例(95.2%)接受缩宫素,190例(19.9%)最大剂量率超过20毫单位/分。多变量分析显示,超过20毫单位/分与剖宫产、围产期感染、产后出血或新生儿重症监护室入院均无显著关联,作者认为缩宫素给药应个体化而非基于任意阈值。
要点
- 在955例接受缩宫素的产妇中,190例(19.9%)最大剂量率超过20毫单位/分。
- 多变量分析中,最大剂量率超过20毫单位/分与剖宫产(aOR 1.57,95%CI 1.00-2.46)无显著关联。
- 超过20毫单位/分与围产期感染、产后出血、新生儿重症监护室入院均无显著关联。
核心结论
- 多变量分析中,缩宫素最大剂量率超过20毫单位/分与母体或围产不良结局无显著差异。
- 作者认为这些数据提示缩宫素给药应个体化,不应基于任意阈值。
研究设计与样本
- 本研究为双盲、单中心随机对照试验的二次分析,原试验纳入36周及以上自然临产的单胎初产妇,按1:1随机接受高剂量缩宫素滴定方案(初始-增量速率6毫单位/分)或标准剂量滴定方案(初始-增量速率2毫单位/分)以加强宫缩。
- 研究方案未规定缩宫素最大剂量率上限;本二次分析纳入955例(95.2%)接受缩宫素的参与者,其中190例(19.9%)最大剂量率超过20毫单位/分。
主要发现
- 最大剂量率超过20毫单位/分的参与者年龄较大,更可能以胎膜早破为试验入选指征、合并妊娠期高血压疾病、接受产时硫酸镁输注,且缩宫素使用时间更长。
- 最大剂量率超过20毫单位/分者剖宫产更频繁,但多数(74%)仍经阴道分娩。
- 多变量分析中,最大剂量率超过20毫单位/分与剖宫产(aOR 1.57,95%CI 1.00-2.46)、围产期感染(aOR 0.69,95%CI 0.41-1.19)、产后出血(aOR 1.37,95%CI 0.70-2.71)及新生儿重症监护室入院(aOR 1.72,95%CI 0.89-3.31)均无显著关联。
- 85%的自发性阴道分娩发生于最大缩宫素剂量率20毫单位/分或以下,但更高最大剂量率下仍有阴道分娩发生。
- 新生儿重症监护室入院及复合严重新生儿疾病和死亡病例的累积比例随缩宫素剂量率升高而增加,即使在最大剂量率20毫单位/分或以下亦然。
临床怎么用
- 作者认为缩宫素给药应个体化至每位患者,不应基于任意阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite lack of evidence for a safety threshold for oxytocin dose rate, many hospital protocols specify a maximum rate. We investigated whether exceeding 20 milliunits/min of oxytocin was associated with adverse outcomes. METHODS: This is a secondary analysis of a double-blind, single-center, randomized controlled trial of nulliparous patients with singleton gestations at 36 weeks of gestation or later who presented in spontaneous labor randomized 1:1 to either a high-dose oxytocin titration regimen (initial-incremental rate of 6 milliunits/min) or standard-dose titration regimen (initial-incremental rate of 2 milliunits/min) for labor augmentation. A maximum oxytocin dose rate limit was not specified in the study protocol. For this secondary analysis, outcomes of participants who received oxytocin and exceeded a dose rate of 20 milliunits/min at any point in labor were compared with those whose rate remained at 20 milliunits/min or less. In addition, the cumulative proportions of labor and birth outcomes were calculated for each maximum dose rate of oxytocin reached among this study cohort. RESULTS: Of the 1,003 participants in the parent trial, 955 (95.2%) received oxytocin, as planned, and were included, with 190 (19.9%) exceeding a maximum dose rate of 20 milliunits/min. Those who exceeded 20 milliunits/min were older and were more likely to have rupture of membranes as their trial entry indication, have hypertensive disorders of pregnancy, receive intrapartum magnesium sulfate infusion, and receive oxytocin for longer. Those whose maximum rates exceeded 20 milliunits/min underwent cesarean delivery more frequently, but the majority (74%) still delivered vaginally. In multivariable analyses, there were no significant associations between maximum oxytocin dose rates greater than 20 milliunits/min and cesarean delivery (adjusted odds ratio [aOR] 1.57, 95% CI 1.00-2.46), peripartum infection (aOR 0.69, 95% CI 0.41-1.19), postpartum hemorrhage (aOR 1.37, 95% CI 0.70-2.71), or neonatal intensive care unit (NICU) admission (aOR 1.72, 95% CI 0.89-3.31). Although 85% of spontaneous vaginal deliveries occurred at maximum oxytocin dose rates of 20 milliunits/min or less, vaginal deliveries continued to occur at higher maximum dose rates. The cumulative proportions of NICU admissions and composite severe neonatal morbidity and mortality cases increased with increasing oxytocin dose rates even with maximum oxytocin dose rates at 20 milliunits/min or less. CONCLUSION: In multivariable analyses, there are no significant differences in maternal or perinatal adverse outcomes based on exceeding 20 milliunits/min of oxytocin. These data suggest that oxytocin dosing should be individualized to each patient and not be based on arbitrary thresholds. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT02487797.
引用
- Son M, Roy A, Grobman WA, et al. Maximum Dose Rate of Intrapartum Oxytocin Infusion and Associated Obstetric and Perinatal Outcomes. Obstet Gynecol. 2023. PMID: 36649339. doi:10.1097/AOG.0000000000005058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。